Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
Interventions
Ravulizumab
Eculizumab
Locations
120
United States
Research Site
Los Angeles, California, United States
Research Site
Whittier, California, United States
Research Site
Fort Worth, Texas, United States
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Start Date
December 12, 2016
Primary Completion Date
February 28, 2023
Completion Date
February 28, 2023
Last Updated
May 14, 2024
NCT05876312
NCT06312644
NCT03520647
NCT07152288
NCT06294301
NCT07108023
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions